Optimizing Antipseudomonal Therapy in Critical Care

ABSTRACT

Pseudomonas aeruginosa is a common and important pathogen in the critically ill. It combines environmental hardiness with genomic plasticity and is well adapted to the various niches available in the intensive care unit (ICU). Unresolved arguments over the value of dual versus monotherapy relate primarily to rapidity of killing and to the avoidance of therapeutic failure due to antibiotic resistance. Increasing resistance to conventional antibiotics means that we need to be aware of the factors that promote the success of this pathogen in the ICU, and of emerging alternative strategies. This review focuses on an understanding of the underlying issues and on the practical aspects of prescribing, particularly in the ICU.

KEYWORDS

Pseudomonas aeruginosa - antibiotic resistance - biofilm - quorum sensing - therapy - bacteriophage

REFERENCES

• 1 Bodmann K F. Current guidelines for the treatment of severe pneumonia and sepsis.  Chemotherapy. 2005;  51 227-233
• 2 Obritsch M D, Fish D N, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.  Pharmacotherapy. 2005;  25 1353-1364
• 3 Loeffler J M, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units.  Scand J Infect Dis. 2003;  35 843-850
• 4 Miller J F, Mekalanos J J, Falkow S. Coordinate regulation and sensory transduction in the control of bacterial virulence.  Science. 1989;  243 916-922
• 5 Parsek M R, Greenberg E P. Sociomicrobiology: the connections between quorum sensing and biofilms.  Trends Microbiol. 2005;  13 27-33
• 6 Bassler B L. Small talk: cell-to-cell communication in bacteria.  Cell. 2002;  109 421-424
• 7 Bassler B L, Losick R. Bacterially speaking.  Cell. 2006;  125 237-246
• 8 Valenzuela J K, Thomas L, Partridge S R, van der Reijden T, Dijkshoorn L, Iredell J. Horizontal gene transfer within a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii .  J Clin Microbiol. 2007;  45 453-460
• 9 Branda S S, Vik S, Friedman L, Kolter R. Biofilms: the matrix revisited.  Trends Microbiol. 2005;  13 20-26
• 10 Hogan D, Kolter R. Why are bacteria refractory to antimicrobials?.  Curr Opin Microbiol. 2002;  5 472-477
• 11 Watnick P, Kolter R. Biofilm, city of microbes.  J Bacteriol. 2000;  182 2675-2679
• 12 Foster P L. Stress responses and genetic variation in bacteria.  Mutat Res. 2005;  569 3-11
• 13 Warner D F, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.  Clin Microbiol Rev. 2006;  19 558-570
• 14 Nickel J C, Ruseska I, Wright J B, Costerton J W. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material.  Antimicrob Agents Chemother. 1985;  27 619-624
• 15 Espedido B, Iredell J, Thomas L, Zelynski A. Wide dissemination of a carbapenemase plasmid among gram-negative bacteria: implications of the variable phenotype.  J Clin Microbiol. 2005;  43 4918-4919
• 16 Iredell J R, Sintchenko V. Screening for antibiotic resistant gram-negative bacteria.  Lancet Infect Dis. 2006;  6 316-317
• 17 Peleg A Y, Potoski B A, Rea R et al.. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.  J Antimicrob Chemother. 2007;  59 128-131
• 18 Rahal J J, Urban C, Horn D et al.. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella .  JAMA. 1998;  280 1233-1237
• 19 Rodrigues C, Shenai S, Sadani M et al.. Multidrug-resistant tuberculosis in Mumbai: it's only getting worse.  Int J Tuberc Lung Dis. 2006;  10 1421-1422
• 20 Sintchenko V, Iredell J R, Gilbert G L, Coiera E. What do physicians think about evidence-based antibiotic use in critical care? A survey of Australian intensivists and infectious disease practitioners.  Intern Med J. 2001;  31 462-469
• 21 Di Bonaventura G, Picciani C, Spedicato I, Piccolomini R. E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach.  New Microbiol. 2004;  27 263-272
• 22 Ermertcan S, Hosgor M, Tunger O, Cosar G. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.  Scand J Infect Dis. 2001;  33 818-821
• 23 Piccoli L, Guerrini M, Felici A, Marchetti F. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa .  J Chemother. 2005;  17 355-360
• 24 Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.  Cochrane Database Syst Rev. 2006;  CD003344
• 25 Korzeniowski O, Sande M A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study.  Ann Intern Med. 1982;  97 496-503
• 26 Ibrahim E H, Sherman G, Ward S, Fraser V J, Kollef M H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.  Chest. 2000;  118 146-155
• 27 Iregui M, Ward S, Sherman G, Fraser V J, Kollef M H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.  Chest. 2002;  122 262-268
• 28 Sebat F, Johnson D, Musthafa A A et al.. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients.  Chest. 2005;  127 1729-1743
• 29 Rodriguez A, Mendia A, Sirvent J M et al.. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock.  Crit Care Med. 2007;  35 1493-1498
• 30 Mesaros N, Nordmann P, Plesiat P et al.. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.  Clin Microbiol Infect. 2007;  13 560-578
• 31 Santos Filho L, Eagye K J, Kuti J L, Nicolau D P. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.  Clin Microbiol Infect. 2007;  13 579-585
• 32 Bliziotis I A, Michalopoulos A, Kasiakou S K et al.. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials.  Mayo Clin Proc. 2005;  80 1146-1156
• 33 Rahal J J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.  Clin Infect Dis. 2006;  43(Suppl 2) S95-S99
• 34 Putnam S D, Sanders J W, Tribble D R et al.. Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.  Antimicrob Agents Chemother. 2005;  49 2571-2572
• 35 Villers D, Espaze E, Coste-Burel M et al.. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology.  Ann Intern Med. 1998;  129 182-189
• 36 Spicer WJ Antibiotic Guidelines. 12th ed. Melbourne; Therapeutic Guidelines Ltd. 2003
• 37 Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection.  J Cyst Fibros. 2005;  4(Suppl 2) 49-54
• 38 LeClerc J E, Cebula T A. Pseudomonas survival strategies in cystic fibrosis.  Science. 2000;  289 391-392
• 39 Macia M D, Blanquer D, Togores B, Sauleda J, Perez J L, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.  Antimicrob Agents Chemother. 2005;  49 3382-3386
• 40 Cohn R C, Jacobs M, Aronoff S C. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.  Antimicrob Agents Chemother. 1988;  32 395-396
• 41 Middleton P G, Kidd T J, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex.  Eur Respir J. 2005;  26 305-308
• 42 Stone R. Bacteriophage therapy: Stalin's forgotten cure.  Science. 2002;  298 728-731
• 43 Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage.  Antimicrob Agents Chemother. 2004;  48 3817-3822
• 44 Wang J, Hu B, Xu M et al.. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa .  Int J Mol Med. 2006;  17 309-317
• 45 Bull J J, Millstein J, Orcutt J, Wichman H A. Evolutionary feedback mediated through population density, illustrated with viruses in chemostats.  Am Nat. 2006;  167 E39-E51
• 46 Hentzer M, Wu H, Andersen J B et al.. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors.  EMBO J. 2003;  22 3803-3815
• 47 Rasmussen T B, Givskov M. Quorum sensing inhibitors: a bargain of effects.  Microbiology. 2006;  152 895-904
• 48 Rice S A, McDougald D, Kumar N, Kjelleberg S. The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections.  Curr Opin Investig Drugs. 2005;  6 178-184